Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Inpatient Double-Blind Placebo-Controlled Withdrawal Study of 3,4-Diaminopyridine Base (3,4-DAP) in Subjects With Known Lambert-Eaton Myasthenic Syndrome

NCT01511978 is registered in ClinicalTrials.gov with Jacobus Pharmaceutical as lead sponsor.

NCT NCT01511978
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01511978 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Inpatient Double-Blind Placebo-Controlled Withdrawal Study of 3,4-Diaminopyridine Base (3,4-DAP) in Subjects With Known Lambert-Eaton Myasthenic Syndrome
Lead sponsor
Jacobus Pharmaceutical
Phase
Phase 2
Overall status
Completed
Start date
January 31, 2012
Completion date
July 31, 2015
Enrollment
32 (actual)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

eaton-lambert myasthenic syndrome, lambert-eaton myasthenic syndrome